Skip to main content

Table 2 Pathway utilization and compliance

From: Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy

Variable

Pre Group (n = 276)

ERAS Group (n = 96)

p-value

Preoperative Acetaminophen, n (%)

48 (17%)

86 (89%)

< 0.001+

Preoperative Gabapentin, n (%)

35 (13%)

86 (89%)

< 0.001+

Scopolamine patch, n (%)

62 (22%)

73 (76%)

< 0.001+

Nerve Block, n (%)

51 (18%)

PVB: 32

Pecs I/II: 18

84 (88%)

PVB: 2

Pecs I/II: 81

< 0.001+

Intraoperative TIVA, n (%)

23 (8%)

32 (33%)

< 0.001+

Intraoperative Ondansetron, n (%)

0 mg: 15 (5%)

4 mg: 245 (89%)

8 mg: 14 (5%)

12 mg: 0 (0%)

0 mg: 6 (6%)

4 mg: 88 (92%)

8 mg: 1 (1%)

12 mg: 1 (1%)

0.11+

Intraoperative Dexamethasone, n (%)

0 mg: 45 (16%)

4 mg: 100(36%)

6 mg: 69 (25%)

8 mg: 49 (18%)

10 mg: 12 (4%)

0 mg: 2 (2%)

4 mg: 22 (23%)

6 mg: 20 (21%)

8 mg: 51 (53%)

10 mg: 1 (1%)

< 0.001+

  1. +P-values calculated from chi-square test; TIVA = total intravenous anesthesia